Unlock instant, AI-driven research and patent intelligence for your innovation.

Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof

A compound, SO2R1 technology, applied in the field of bile acid derivatives and its preparation, can solve the problem of increasing energy consumption

Active Publication Date: 2021-01-26
ENANTA PHARM INC
View PDF15 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

While activation of this membrane receptor in macrophages reduces pro-inflammatory cytokine production (Kawamata, Y., et al., J. Biol. Chem. 2003, 278, 9435-9440), in adipocytes and muscle Stimulation of TGR5 by BA in cells increases energy expenditure (Watanabe, M. et al., Nature. 2006, 439, 484-489)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
  • Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
  • Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0377]

[0378] Step 1-1

[0379]

[0380] at 0°C and N 2 MEMCl was added to a stirred solution of (1-1) (4.35 g, 10.0 mmol) and DIPEA (10.3 mL, 30 mmol) in DCM (100 mL). The resulting reaction mixture was allowed to warm to room temperature and stirred overnight, then quenched with water (50 mL) and 1 N HCl (50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and concentrated to give 6.5 g of crude product (1-2), which was directly used in the next step. LC-MS observed value 2M+NH 4 = 1062.83 (calculated value 1062.81).

[0381] Step 1-2

[0382]

[0383] First at 0°C and N 2 The above mentioned crude product (1-2) (4.18 g, 8.0 mmol) was dissolved in THF (30 mL), anhydrous MeOH (1.28 ml, 32 mmol) was added followed by slow addition of LiBH 4 (697 mg, 32 mmol). The mixture was stirred at 0 °C for 6 h, TLC and LC-MS analysis showed partial conversion of starting material, then more LiBH was added 4 (348 mg, 16 mmol). The mixture was all...

Embodiment 2

[0391]

[0392] Step 2-1

[0393]

[0394] A solution of alcohol (1-3) (99 mg, 0.2 mmol) and CDI (65 mg, 0.4 mmol) in MeCN / THF (1 / 1, 1 mL) was stirred at room temperature for 1.5 h before addition of cyclohexanesulfonamide ( 98mg, 0.6mmol) and DBU (89μL, 0.6mmol). The resulting reaction mixture was stirred at room temperature for 1 h, then quenched with brine and extracted with ethyl acetate. The combined organic layers were washed with brine and concentrated. The residue was purified by silica gel chromatography using hexane / acetone (100 / 0 to 60 / 40, 10 min) to give sulfonylcarbamate (2-1) (100 mg, 73%) as a colorless oil . LC-MS observed M-1 = 682.36 (calculated 682.44).

[0395] Step 2-2

[0396]

[0397] Carbamate (2-1) (100 mg, 0.15 mmol) was first dissolved in THF (3 mL) at room temperature. Then 37% HCl (0.1 mL, 1.2 mmol) was added. The mixture was stirred at room temperature for 1 h, washed with saturated NaHCO 3Quenched and extracted with ethyl acetate...

Embodiment 3

[0399]

[0400] Step 3-1

[0401]

[0402] A solution of alcohol (1-3) (99 mg, 0.2 mmol) and CDI (65 mg, 0.4 mmol) in MeCN / THF (1 / 1, 1 mL) was stirred at room temperature for 1.5 h, then 4-tert-butylaniline was added (90 mg, 0.6 mmol) and DBU (89 μL, 0.6 mmol). The resulting reaction mixture was stirred at room temperature for 18 h, then quenched with brine and extracted with ethyl acetate. The combined organic layers were washed with brine and concentrated. The residue was purified by silica gel chromatography using hexane / acetone (100 / 0 to 60 / 20, 10 minutes) to give carbamate (3-1) (87 mg, 65%) as a colorless oil. LC-MS observation valueM+NH 4 =687.64 (calculated value 687.53).

[0403] Step 3-2

[0404]

[0405] Carbamate (3-1) (87 mg, 0.13 mmol) was first dissolved in THF (3 mL) at room temperature. Then 37% HCl (0.1 mL, 1.2 mmol) was added. The mixture was stirred at room temperature for 1 h, washed with saturated NaHCO 3 Quenched and extracted with ethyl...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a compound represented by formula I or a pharmaceutically acceptable salt, stereoisomer, solvate, hydrate or combination thereof, (I). The invention also provides pharmaceutical compositions comprising these compounds and methods of using the compounds to treat FXR-mediated or TGR5-mediated diseases or conditions.

Description

[0001] related application [0002] This application claims priority to US Application No. 62 / 140,927, filed March 31, 2015, and US Application No. 62 / 287,267, filed January 26, 2016. The entire teachings of the above applications are incorporated herein by reference. technical field [0003] The present invention generally relates to compounds useful as FXR / TGR5 modulators and pharmaceutical compositions thereof. In particular, the present invention relates to bile acid derivatives and methods for their preparation and use. [0004] Background of the invention [0005] Farnesoid X receptor (FXR) is an orphan nuclear receptor initially identified from a rat liver cDNA library (BM.Forman et al., Cell, 1995, 81(5), 687-693), which is related to insect ecdysone most closely related to receptors. FXR is a member of the nuclear receptor family of ligand-activated transcription factors, which includes receptors for steroids, retinoids and thyroid hormones (DJ. Mangelsdorf et al....

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/575A61P1/16
CPCC07J9/00C07J9/005C07J41/0088C07J51/00C07J41/0055C07J43/003A61P1/00A61P1/16A61P13/12A61P3/00A61P31/12A61P35/00A61P3/06A61P37/02A61P37/06A61P43/00A61P5/50A61P9/00A61P9/10A61P9/12A61P3/10C07J41/005A61K31/57A61K31/575A61K31/58
Inventor 王国强Y·S·奥尔沈瑞超邢学超龙江戴鹏B·格兰杰J·何
Owner ENANTA PHARM INC